Kraig Biocraft Laboratories to Launch Operations at New Southeast Asia Production Facility This Week
Rhea-AI Summary
Kraig Biocraft Laboratories (OTCQB: KBLB), a biotechnology company specializing in spider silk technology, has announced the launch of operations at its new production facility in Southeast Asia. The facility, established through a government agency collaboration, will begin its first full production cycle this week.
The site will produce the company's BAM-1 spider silk hybrid parent lines and several new transgenic strains introduced in early 2025. These next-generation strains are designed to deliver higher silk yields, improved quality, and enhanced robustness. The facility represents a strategic expansion of Kraig Labs' production capabilities as it prepares for anticipated product deliveries to potential customers.
Positive
- Strategic expansion of production capacity through new Southeast Asia facility
- Government agency collaboration providing operational security
- Introduction of new transgenic strains with improved yield and quality potential
- Enhanced production capabilities for anticipated customer deliveries
Negative
- No specific production targets or timelines provided
- Early stage of operations with unproven commercial scalability
- Dependent on successful development of new transgenic strains
News Market Reaction
On the day this news was published, KBLB declined 2.53%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
New site established in collaboration with a government agency to bolster spider silk output and market readiness
ANN ARBOR, Mich., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, announces that it will begin operations this week at its newest production facility. This milestone marks the launch of the first full production cycle at the site. This production site was secured earlier this summer through an agreement with a government agency in Southeast Asia.
This facility is designed to provide expanded capacity and operational security as Kraig Labs scales up its recombinant spider silk manufacturing. The site will play a key role in supporting the Company’s growth strategy as it prepares for anticipated product deliveries to potential customers and strategic markets.
This inaugural production cycle will include the rearing of the Company's parent lines for its BAM-1 spider silk hybrid, as well as several new transgenic lines that were introduced into the production environment in the first half of 2025. These next-generation strains are part of the Company’s ongoing development pipeline. These new strains are expected to complement the existing BAM-1 hybrids while delivering higher silk yields, improved silk quality, and enhanced robustness.
"This facility represents a critical step forward in our production capabilities," said Founder and CEO of Kraig Labs, Kim Thompson. "Our collaboration with government agencies in the region has created a robust platform for sustainable growth, allowing us to expand our operational footprint while maintaining close control over the quality and consistency of our spider silk."
Kraig Labs expects this production cycle to lay the groundwork for future expansion and delivery readiness of the highest-grade fibers, as it continues scaling its proprietary silk technology.
For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.
For details about other recent Kraig Labs advancements, please watch the Company's investor conference at www.kraiglabs.com/videos or on the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
* For a description of our historical leadership in this technology, please follow this link https://www.kraiglabs.com/world-leader/
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, Inc.
(720) 288-8495
ir@KraigLabs.com
FAQ
What is the significance of Kraig Biocraft's new Southeast Asia facility?
What products will KBLB manufacture at the new facility?
When will Kraig Biocraft's new production facility begin operations?
How does this facility impact KBLB's business strategy?
What improvements are expected from KBLB's new transgenic strains?
